Petros Isaakidis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6166951/publications.pdf

Version: 2024-02-01

117 papers	3,016 citations	249298 26 h-index	223390 49 g-index
117 all docs	117 docs citations	117 times ranked	3638 citing authors

#	Article	IF	Citations
1	Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa. Tropical Medicine and Infectious Disease, 2022, 7, 21.	0.9	2
2	Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India. PLoS ONE, 2022, 17, e0263759.	1.1	7
3	Acceptability of unsupervised peer-based distribution of HIV oral self-testing for the hard-to-reach in rural KwaZulu Natal, South Africa: Results from a demonstration study. PLoS ONE, 2022, 17, e0264442.	1.1	3
4	Being heard on all-oral therapy for resistant tuberculosis. Lancet Infectious Diseases, The, 2022, 22, 923-924.	4.6	2
5	One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India. Clinical Infectious Diseases, 2021, 73, e3496-e3504.	2.9	18
6	Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India. PLoS ONE, 2021, 16, e0246639.	1.1	11
7	Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: A qualitative study. PLoS ONE, 2021, 16, e0248408.	1.1	21
8	Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic. The Lancet Child and Adolescent Health, 2021, 5, 159-161.	2.7	11
9	Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Clinical Infectious Diseases, 2021, 73, e3563-e3571.	2.9	23
10	Mental health interventions for rifampicin-resistant tuberculosis patients with alcohol use disorders, Zhytomyr, Ukraine. Journal of Infection in Developing Countries, 2021, 15, 25S-33S.	0.5	0
11	â€˜Only twice a yearâ€™: a qualitative exploration of 6-month antiretroviral treatment refills in adherence clubs for people living with HIV in Khayelitsha, South Africa. BMJ Open, 2020, 10, e037545.	0.8	22
12	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, The, 2020, 396, 402-411.	6.3	49
13	Correspondence regarding â€œDelamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africaâ€• European Respiratory Journal, 2020, 56, 2000837.	3.1	2
14	Preparedness of outpatient health facilities for ambulatory treatment with all-oral short DR-TB treatment regimens in Zhytomyr, Ukraine: a cross-sectional study. BMC Health Services Research, 2020, 20, 890.	0.9	0
15	Setting up a nurse-led model of care for management of hypertension and diabetes mellitus in a high HIV prevalence context in rural Zimbabwe: a descriptive study. BMC Health Services Research, 2020, 20, 486.	0.9	11
16	Yield of Systematic Longitudinal Screening of Household Contacts of Pre-Extensively Drug Resistant (PreXDR) and Extensively Drug Resistant (XDR) Tuberculosis Patients in Mumbai, India. Tropical Medicine and Infectious Disease, 2020, 5, 83.	0.9	2
17	Routine viral load monitoring and enhanced adherence counselling at a public ART centre in Mumbai, India. PLoS ONE, 2020, 15, e0232576.	1.1	11
18	Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges. PLoS ONE, 2020, 15, e0234651.	1.1	9

#	Article	IF	Citations
19	Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2020, 8, 383-394.	5.2	155
20	Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa. EClinicalMedicine, 2020, 20, 100290.	3.2	14
21	Improving pediatric TB diagnosis in North Kivu (DR Congo), focusing on a clinical algorithm including targeted Xpert MTB/RIF on gastric aspirates. Conflict and Health, 2020, 14, 26.	1.0	3
22	Partner Notification Approaches for Sex Partners and Children of Human Immunodeficiency Virus Index Cases in CÃ´te d'Ivoire. Sexually Transmitted Diseases, 2020, 47, 450-457.	0.8	9
23	GeneXpert and Community Health Workers Supported Patient Tracing for Tuberculosis Diagnosis in Conflict-Affected Border Areas in India. Tropical Medicine and Infectious Disease, 2020, 5, 1.	0.9	21
24	Access to health services for men who have sex with men and transgender women in Beira, Mozambique: A qualitative study. PLoS ONE, 2020, 15, e0228307.	1.1	18
25	New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India. International Journal of Tuberculosis and Lung Disease, 2020, 24, 1265-1271.	0.6	12
26	Adapting TB services during the COVID-19 pandemic in Mumbai, India. International Journal of Tuberculosis and Lung Disease, 2020, 24, 1119-1121.	0.6	25
27	Title is missing!. , 2020, 15, e0234651.		0
28	Title is missing!. , 2020, 15, e0234651.		0
29	Title is missing!. , 2020, 15, e0234651.		0
30	Title is missing!. , 2020, 15, e0234651.		0
31	Title is missing!. , 2020, 15, e0234651.		0
32	Title is missing!. , 2020, 15, e0234651.		0
33	Are they there yet? Linkage of patients with tuberculosis to services for tobacco cessation and alcohol abuse â€“ a mixed methods study from Karnataka, India. BMC Health Services Research, 2019, 19, 90.	0.9	14
34	Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis. Lancet Infectious Diseases, The, 2019, 19, 470.	4.6	14
35	Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2019, 25, 441-450.	2.0	16
36	Beyond â€˜cure' and â€˜treatment success': quality of life of patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2019, 23, 73-81.	0.6	33

#	Article	IF	Citations
37	Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting. International Journal of Tuberculosis and Lung Disease, 2019, 23, 1017-1023.	0.6	9
38	Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India. PLoS ONE, 2019, 14, e0225631.	1.1	7
39	Breast Tuberculosis in Women: A Systematic Review. American Journal of Tropical Medicine and Hygiene, 2019, 101, 12-21.	0.6	10
40	Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 536-544.	4.6	106
41	Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. European Respiratory Journal, 2018, 51, 1800017.	3.1	39
42	Factors associated with death and loss to follow-up in children on antiretroviral care in Mingalardon Specialist Hospital, Myanmar, 2006â€“2016. PLoS ONE, 2018, 13, e0195435.	1.1	8
43	â€œThey donâ€™t like usâ€¦â€• Barriers to antiretroviral and opioid substitution therapy among homeless HIV positive people who inject drugs in Delhi: A mixed method study. PLoS ONE, 2018, 13, e0203262.	1.1	20
44	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452
45	Integrating screening for non-communicable diseases and their risk factors in routine tuberculosis care in Delhi, India: A mixed-methods study. PLoS ONE, 2018, 13, e0202256.	1.1	16
46	Breast tuberculosis in men: A systematic review. PLoS ONE, 2018, 13, e0194766.	1.1	8
47	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2018, 15, e1002591.	3.9	96
48	â€˜I didn't know so many people cared about me': support for patients who interrupt drug-resistant TB treatment. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1023-1030.	0.6	13
49	Yield of facility-based verbal screening amongst household contacts of patients with multi-drug resistant tuberculosis in Pakistan. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 7, 22-27.	0.6	6
50	Life in the time of antiretrovirals in South Africa. Lancet HIV,the, 2017, 4, e95-e96.	2.1	0
51	High burden of malaria and anemia among tribal pregnant women in a chronic conflict corridor in India. Conflict and Health, 2017, 11, 10.	1.0	22
52	Effect of previous utilization and out-of-pocket expenditure on subsequent utilization of a state led public-private partnership scheme â€œChiranjeevi Yojanaâ€•to promote facility births in Gujarat, India. BMC Health Services Research, 2017, 17, 302.	0.9	1
53	The contribution of a non-governmental organisationâ€™s Community Based Tuberculosis Care Programme to case finding in Myanmar: trend over time. Infectious Diseases of Poverty, 2017, 6, 51.	1.5	6
54	Different challenges, different approaches and related expenditures of community-based tuberculosis activities by international non-governmental organizations in Myanmar. Infectious Diseases of Poverty, 2017, 6, 59.	1.5	6

#	Article	IF	Citations
55	Active case-finding for tuberculosis by mobile teams in Myanmar: yield and treatment outcomes. Infectious Diseases of Poverty, 2017, 6, 77.	1.5	18
56	DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting. PLoS ONE, 2017, 12, e0178054.	1.1	9
57	Alarming prevalence and clustering of modifiable noncommunicable disease risk factors among adults in Bhutan: a nationwide cross-sectional community survey. BMC Public Health, 2017, 17, 975.	1.2	39
58	â€œI Wasted 3 Years, Thinking Itâ€™s Not a Problemâ€• Patient and Health System Delays in Diagnosis of Leprosy in India: A Mixed-Methods Study. PLoS Neglected Tropical Diseases, 2017, 11, e0005192.	1.3	32
59	Before the bombing: High burden of traumatic injuries in Kunduz Trauma Center, Kunduz, Afghanistan. PLoS ONE, 2017, 12, e0165270.	1.1	14
60	Recurrent tuberculosis and associated factors: A five - year countrywide study in Uzbekistan. PLoS ONE, 2017, 12, e0176473.	1.1	14
61	Low mother-to-child HIV transmission rate but high loss-to-follow-up among mothers and babies in Mandalay, Myanmar; a cohort study. PLoS ONE, 2017, 12, e0184426.	1.1	23
62	â€œWhen Treatment Is More Challenging than the Diseaseâ€• A Qualitative Study of MDR-TB Patient Retention. PLoS ONE, 2016, 11, e0150849.	1.1	63
63	Paragonimiasis in tuberculosis patients in Nagaland, India. Global Health Action, 2016, 9, 32387.	0.7	8
64	Leprosy trends at a tertiary care hospital in Mumbai, India, from 2008 to 2015. Global Health Action, 2016, 9, 32962.	0.7	8
65	Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key: Table 1.. Clinical Infectious Diseases, 2016, 62, S238-S243.	2.9	60
66	Utilization of the state led public private partnership program â€œChiranjeevi Yojanaâ€•to promote facility births in Gujarat, India: a cross sectional community based study. BMC Health Services Research, 2016, 16, 266.	0.9	6
67	Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. International Journal of Tuberculosis and Lung Disease, 2016, 20, 430-434.	0.6	62
68	The tuberculosis emergency in eastern Europe. Lancet HIV,the, 2016, 3, e107-e108.	2.1	3
69	Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India. PLoS ONE, 2016, 11, e0162138.	1.1	26
70	Screening patients with tuberculosis for diabetes mellitus in Ampara, Sri Lanka. Public Health Action, 2015, 5, 150-152.	0.4	13
71	Infective endocarditis in Ethiopian children: a hospital based review of cases in Addis Ababa. Pan African Medical Journal, 2015, 20, 75.	0.3	12
72	Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Greater Metropolitan Mumbai: Trends over Time. PLoS ONE, 2015, 10, e0116798.	1.1	58

#	Article	IF	Citations
73	Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria. PLoS ONE, 2015, 10, e0120161.	1.1	28
74	â€œThey Know, They Agree, but They Donâ€™t Doâ€• The Paradox of Tuberculosis Case Notification by Private Practitioners in Alappuzha District, Kerala, India. PLoS ONE, 2015, 10, e0123286.	1.1	37
75	The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh. PLoS ONE, 2015, 10, e0129155.	1.1	15
76	Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clinical Infectious Diseases, 2015, 61, 1255-1262.	2.9	53
77	Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients. European Respiratory Journal, 2015, 46, 271-274.	3.1	24
78	Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 969-978.	0.6	99
79	Linezolid in drug-resistant tuberculosis: haste makes waste. European Respiratory Journal, 2015, 46, 1844-1846.	3.1	3
80	HIV viral load messages should go viral in India. Lancet HIV,the, 2015, 2, e414-e415.	2.1	2
81	Burden of isolation for multidrug-resistant organisms in a tertiary public hospital in Southern Brazil. American Journal of Infection Control, 2015, 43, 188-190.	1.1	4
82	Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study. PLoS ONE, 2015, 10, e0128907.	1.1	40
83	Loss-To-Follow-Up on Multidrug Resistant Tuberculosis Treatment in Gujarat, India: The WHEN and WHO of It. PLoS ONE, 2015, 10, e0132543.	1.1	23
84	Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?. PLoS ONE, 2015, 10, e0144936.	1.1	21
85	Outcomes in Adolescents Undergoing Treatment for Drug-Resistant Tuberculosis in Mumbai. Archives of Pediatric Infectious Diseases, 2015, 3, .	0.1	2
86	Self-Administered Tuberculosis Treatment Outcomes in a Tribal Population on the Indo-Myanmar Border, Nagaland, India. PLoS ONE, 2014, 9, e108186.	1.1	7
87	Alarming Levels of Drug-Resistant Tuberculosis in HIV-Infected Patients in Metropolitan Mumbai, India. PLoS ONE, 2014, 9, e110461.	1.1	52
88	High attrition among HIV-infected patients with advanced disease treated in an intermediary referral center in Maputo, Mozambique. Global Health Action, 2014, 7, 23758.	0.7	20
89	Caseload, management and treatment outcomes of patients with hypertension and/or diabetes mellitus in a primary health care programme in an informal setting. Tropical Medicine and International Health, 2014, 19, 47-57.	1.0	29
90	Treating drug-resistant tuberculosis in a low-intensity chronic conflict setting in India. Conflict and Health, 2014, 8, 25.	1.0	6

#	Article	IF	Citations
91	Patch-testing for the management of hypersensitivity reactions to second-line anti-tuberculosis drugs: a case report. BMC Research Notes, 2014, 7, 537.	0.6	2
92	Calling tuberculosis a social diseaseâ€"an excuse for complacency?. Lancet, The, 2014, 384, 1095.	6.3	13
93	Zero tuberculosis at the latest International AIDS Congress in Asia and the Pacific?. The Lancet Global Health, 2014, 2, e204-e205.	2.9	0
94	HIV, multidrug-resistant TB and depressive symptoms: when three conditions collide. Global Health Action, 2014, 7, 24912.	0.7	23
95	Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India. Global Health Action, 2014, 7, 24861.	0.7	24
96	Directly-Observed and Self-Administered Tuberculosis Treatment in a Chronic, Low-Intensity Conflict Setting in India. PLoS ONE, 2014, 9, e92131.	1.1	10
97	Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria. PLoS ONE, 2014, 9, e94393.	1.1	29
98	Ocular inflammatory disease and ocular tuberculosis in a cohort of patients co-infected with HIV and multidrug-resistant tuberculosis in Mumbai, India: a cross-sectional study. BMC Infectious Diseases, 2013, 13, 225.	1.3	23
99	Viral Load for HIV Treatment Failure Management: A Report of Eight Drug-Resistant Tuberculosis Cases Co-Infected with HIV Requiring Second-Line Antiretroviral Treatment in Mumbai, India. American Journal of Tropical Medicine and Hygiene, 2013, 89, 1233-1234.	0.6	1
100	â€˜I cry every dayâ€™: experiences of patients coâ€infected with <scp>HIV</scp> and multidrugâ€resistant tuberculosis. Tropical Medicine and International Health, 2013, 18, 1128-1133.	1.0	70
101	HPV infection, cervical abnormalities, and cancer in HIV-infected women in Mumbai, India: 12-month follow-up. International Journal of Women's Health, 2013, 5, 487.	1.1	16
102	Impact on ART initiation of pointâ€ofâ€care CD4 testing at HIV diagnosis among HIVâ€positive youth in Khayelitsha, South Africa. Journal of the International AIDS Society, 2013, 16, 18518.	1.2	46
103	Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India. PLoS ONE, 2013, 8, e68869.	1.1	51
104	High Rate of Hypothyroidism in Multidrug-Resistant Tuberculosis Patients Co-Infected with HIV in Mumbai, India. PLoS ONE, 2013, 8, e78313.	1.1	22
105	Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India. International Health, 2012, 4, 239-245.	0.8	3
106	Tracing patients on antiretroviral treatment lostâ€toâ€followâ€up in an urban slum in India. Journal of Advanced Nursing, 2012, 68, 2399-2409.	1.5	5
107	Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. PLoS ONE, 2012, 7, e40781.	1.1	80
108	Treatment of hypertension in rural Cambodia: results from a 6-year programme. Journal of Human Hypertension, 2011, 25, 241-249.	1.0	12

#	Article	IF	Citations
109	Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. PLoS ONE, 2011, 6, e28066.	1.1	71
110	High survival and treatment success sustained after two and three years of firstâ€line ART for children in Cambodia. Journal of the International AIDS Society, 2010, 13, 11-11.	1.2	31
111	Idiopathic CD4+ T-lymphocytopenia with cryptococcal meningitis: first case report from Cambodia. Tropical Doctor, 2009, 39, 176-177.	0.2	2
112	Screening and Treating Cervical Cancer in HIV-Positive Women in Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 644-646.	0.9	5
113	Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatrics, 2009, 9, 54.	0.7	45
114	Treating 4,000 diabetic patients in Cambodia, a high-prevalence but resource-limited setting: a 5-year study. BMC Medicine, 2009, 7, 33.	2.3	31
115	Evaluation of a Systematic Substitution of Zidovudine for Stavudine-Based HAART in a Program Setting in Rural Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 48-54.	0.9	15
116	Serogroup X in Meningococcal Disease, Western Kenya. Emerging Infectious Diseases, 2007, 13, 944-945.	2.0	35
117	Evaluation of Cluster Randomized Controlled Trials in Sub-Saharan Africa. American Journal of Epidemiology, 2003, 158, 921-926.	1.6	55